| Multinational business finance DK Eiteman, AI Stonehill, MH Moffett Pearson, 2016 | 1693 | 2016 |
| Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era AM Evens, KA David, I Helenowski, B Nelson, D Kaufman, SM Kircher, ... Journal of Clinical Oncology 28 (6), 1038, 2010 | 348 | 2010 |
| Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base KA David, MI Milowsky, J Ritchey, PR Carroll, DM Nanus The Journal of urology 178 (2), 451-454, 2007 | 272 | 2007 |
| Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata S Yang, AM Evens, S Prachand, ATK Singh, S Bhalla, K David, LI Gordon Clinical Cancer Research 16 (19), 4755-4768, 2010 | 122 | 2010 |
| PCI-24781 induces caspase and reactive oxygen species–dependent apoptosis through NF-κB mechanisms and is synergistic with bortezomib in lymphoma cells S Bhalla, S Balasubramanian, K David, M Sirisawad, J Buggy, L Mauro, ... Clinical Cancer Research 15 (10), 3354-3365, 2009 | 115 | 2009 |
| Evaluating risk factors for the development of ifosfamide encephalopathy KA David, J Picus American journal of clinical oncology 28 (3), 277-280, 2005 | 111 | 2005 |
| Electronic Commerce: a managerial perspective T Efraim, L Jae, K David, CH Michael International Edition. New Jersey: Prentice Hall, 2000 | 109 | 2000 |
| Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre … CS Diefenbach, F Hong, RF Ambinder, JB Cohen, MJ Robertson, ... The Lancet Haematology 7 (9), e660-e670, 2020 | 99 | 2020 |
| Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses S Joshi, S Kaur, AJ Redig, K Goldsborough, K David, T Ueda, ... Proceedings of the National Academy of Sciences 106 (29), 12097-12102, 2009 | 94 | 2009 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 89 | 2021 |
| Surveillance of urothelial carcinoma: stage and grade migration, 1993–2005 and survival trends, 1993–2000 KA David, K Mallin, MI Milowsky, J Ritchey, PR Carroll, DM Nanus Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 87 | 2009 |
| Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007) K Mallin, KA David, PR Carroll, MI Milowsky, DM Nanus The Journal of urology 185 (5), 1631-1636, 2011 | 82 | 2011 |
| Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 63 | 2022 |
| Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) R Bannerji, JN Allan, JE Arnason, JR Brown, RH Advani, JA Barnes, ... Blood 134, 762, 2019 | 63 | 2019 |
| Burkitt lymphoma international prognostic index AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ... Journal of clinical oncology 39 (10), 1129-1138, 2021 | 59 | 2021 |
| A phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial … CS Diefenbach, F Hong, KA David, J Cohen, M Robertson, R Advani, ... Blood 128 (22), 1106, 2016 | 54 | 2016 |
| Green growth and climate resilience national strategy for climate change and low carbon development K David, C Megan, C Christian, D Jillian, H Ryan, M Robert, W Mathew, ... Republic of Rwanda, Kigali, 2011 | 41 | 2011 |
| Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma RW Merryman, RA Redd, T Nishihori, J Chavez, Y Nieto, JM Darrah, ... Blood Advances 5 (6), 1648-1659, 2021 | 36 | 2021 |
| Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: A trial of the ECOG‐ACRIN cancer research group (E4412) CS Diefenbach, F Hong, K David, J Cohen, M Roberston, R Advani, ... Hematological Oncology 35, 84-85, 2017 | 35 | 2017 |
| Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma D Ravi, S Sarkar, S Purvey, F Passero, A Beheshti, Y Chen, M Mokhtar, ... Leukemia 34 (5), 1291-1304, 2020 | 34 | 2020 |
